Thank you for joining the weekly webinar! We are admitting audience members from the waiting room. **Please allow a few moments for the webinar to begin.**





HEALEY ALS Platform Trial Weekly Webinars

Guest Speakers

EAP WEBINAR SERIES

with guest speakers Shawn Sarbacker & Dr. Hristelina Ilieva



Thursday May 9th, 2024 5pm EST Shawn Sarbacker Founder of TechVsALS

Hristelina Ilieva, MD, PhD

Clinical Director of Jefferson Health's Weinburg ALS Center



TechVsALS Patient-Led Fundraising For Increased ALS Expanded Access

Shawn Sarbacker & Healey Center for ALS at Mass General Hospital



Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital

For more info, please contact Shawn Sarbacker, <u>shawn@techvsals.org</u> Alexandra Van Strein, <u>avanstrein@mgh.harvard.edu</u> <u>www.techvsals.org</u>

About Shawn







- 56 year-old father of 3 + 1, remarried Aug '22 #ALoveStory
- Lives in Philly; Sports and fitness aficionado
- Runs a global computer chip assembly equipment business for Kulicke & Soffa
- Diagnosed with ALS Nov. 2020
- Under care of "Dr. Merit" at MGH Healey ALS Center since Dec. 2020
- Joined Clene CNM-Au8 Expanded Access
 Program
- Founded the "TechVsALS" campaign in Feb.
 2022

The Problem


- While over 80 promising new ALS therapies are in the clinical trial pipeline...
 - Only 50% of persons with ALS are eligible to participate in clinical trials to gain access to these new life-extending or lifesaving therapies
 - Phase 3 Clinical Trials + FDA approval of successful new therapies takes an average of 3-4 years, which exceeds ALS patients' typical life expectancy

There IS a solution... Expanded Access Programs

Why is Expanded Access critical?

Moral imperative – no more #DyingWaiting

- Expanded clinical learnings
- Supports therapy FDA approval by augmenting primary clinical trial data (& insurance approval...)
- Bridges the availability gap between successful trials and FDA approval



TechVsALS Strategy


- Partnership with the Healey Center
- Solicit sponsorship from entities in the "Tech" world for HEALEY PT Companion Expanded Access program to combat ALS
- Initiate EAP programs at sponsor-designated sites
- Companies, Foundations, Organizations, Individuals

HEALEY ALS Platform Trial

Weekly Q&A - July 13, 2023




HEALEY Platform Trial Companion EAP is Creating a Bridge to Livable ALS



The ALS drug development pipeline is robust Efficient trials are needed to rapidly screen drugs and move them to Phase 3

ALS Clinical Trials Enrolling in the US (Phase 2, 2/3, 3)



More "shots on goal" leads to:

- → More promising therapies available for EAPs
- → More bridges to regulatory approval needed

Note: Trials are listed within the date range in which enrollment began

Kulicke & Soffa sponsors Companion EAP at Jefferson Weinberg ALS Center in Philadelphia

Home - Neurology - ALS - News

NEWS · SEP | 22 | 2022

Healey Center adds Jefferson Weinberg ALS Center as clinical enrolling site for Expanded Access Protocol (EAP) companion program to the HEALEY ALS Platform Trial



treatments.





Ribbon cutting ceremony 31 Aug 2022

K

minutes

FOR INVESTORS

News Releases

Events and Webcasts Corporate Governance Financial Information Stock Information Investor FAQs Contact Us Kulicke & Soffa Supports MGH and Jefferson Health to Increase ALS Patient Access to Potentially Life-Saving Advanced Therapies

SINGAPORE and BOSTON and PHILADELPHIA, Sept. 1, 2022

/PRNewswire/ -- Kulicke and Soffa Industries, Inc. (NASDAQ:KLI

("Kulicke & Soffa", "K&S" or the "Company"), Massachusetts Gen

Hospital and Jefferson Health today announced a multi-year dona

from K&S to establish and support the Multicenter Expanded Acc

Protocol (EAP) Companion Program to the HEALEY ALS Platform

led by the team from the Sean M. Healey & AMG Center for ALS a Massachusetts General Hospital. This program will be expanding to the Jefferson Weinberg ALS Center to provide patients in the Philadelphia area with expanded access to ALS investigational



AL

🖾 🖉

About ALS v Treatments

News 🗧 Kulicke & Soffa Donation Expands Access to Investigational Therapies

Kulicke & Soffa Donation Expands Access to Investigational Therapies

EAP program will help patients who don't qualify for clinical trials

JEFFERSON WEINBERG

SCEN

by Mary Chapman | September 15, 2022

Life Changing Impact



Healey & AMG Center Sean M. Healey & AMG Center for ALS



"We strive to provide ALS patients, including for those that are not eligible for clinical trials, access to promising new therapies with good underlying science. The K&S gift supporting that mission not only established the Weinberg EAP but also has been pivotal in accelerating Expanded Access for ALS patients nationwide."

Access Dr. Merit Cudkowis & AMG ALS Ctr at Muss energy



Advancing

Science

"The EAP gave Joe a chance to receive a treatment that he would not have received otherwise. We are both thankful for the opportunity to have additional hope...it made us feel that Joe was still valued and seen." Joe and Helen Brooks



"EAPs represent hope for those who wouldn't otherwise have access to any investigational therapies that are in clinical trial."

Philip Green

Inclusion



"Since being on EAP my progression has been much, much slower than typical. This has allowed me to live a full life and 'stay in the game' as additional promising therapies come available!"

Hope

Google "Curtis Richter

Hope Experiment"

Shawn Sarbacker

by K&S via TechVsALS & the establishment of the EAP. we have been able to make promising therapies available to patients who wouldn't have access to them. And this is priceless. There is no more pressing need than having access to these therapies"

Dr. Piera Pasinelli, Director, Jefferson Weinberg ALS Ctr





"Thanks to the funds provided

Life Extension

axeALS & Never Surrender Sponsor Three Additional Healey Platform Trial Companion EAP Sites




The axeALS Foundation in partnership with the Sean M. Healey & AMG Center for ALS establishes Expanded Access Protocol (EAP) Program at the University of California, Irvine

The nonprofit's \$486,000 donation provides options for ALS patients

Irvine, CA (March 16, 2023) — The <u>axeALS Foundation</u> is partnering with the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital to establish a new Expanded Access Protocol (EAP) program at the University of California, Irvine. Under the direction of, Namita Goyal, MD, professor of neurology, UCI School of Medicine, and director of UCI Health ALS Services, thanks to multiyear support from the <u>axeALS</u> Foundation, UCI will add expanded access as an option for people living with ALS who do not qualify for trials.

"We are so excited to bring this EAP program to our ALS patients at UC Irvine wh trials and are so thankful to <u>excALS</u> for providing our patients a wonderful opport drugs under investigation," said **Dr. Goyal**





NEWS MAR | 16 | 2023

THE AXEALS FOUNDATION IN PARTNERSHIP WITH THE SEAN M. HEALEY & AMG CENTER FOR ALS ESTABLISHES EXPANDED ACCESS PROTOCOL (EAP) PROGRAM AT THE UNIVERSITY OF CALIFORNIA, IRVINE

THE NONPROFIT'S \$486,000 DONATION PROVIDES OPTIONS FOR ALS PATIENTS



Eric & Amanda Stevens www.axeals.org

Never Surrender Inc. Funding the Fight Against ALS

www.neversurrenderinc.org

ean M. Healey & MG Center for ALS		Find a Docto	or Appointment	s & Referrals	Give Now	Contact Us
	About the Healey & AMG Center for ALS	Clinical Care & Resources	Research Opportunities	Platform Trial	Expanded Access	News & Events

Home - Neurology - ALS - News NEWS · 5 MINUTE READ · MAR | 12 | 2024

In partnership with the Sean M. Healey & AMG Center for ALS, Never Surrender Inc, led by president, David Kolquist establishes Expanded Access Protocol (EAP) Programs at the University of Minnesota and Essentia Health



Juliana Araujo · jaraujo5@mgh.harvard.edu

Boston - The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) and Never Surrender, Inc are partnering to establish two new Expanded Access Protocol (EAP) programs in Minnesota. The site at the University of Minnesota is under the direction of David Walk, MD, F AAN, and Amber Erickson, MD, oversees the new EAP site at Essentia Health. Both sites will be supported by the Healey & AMG Center at MGH. Type News Centers and Departments Neurology, Healey Center for ALS Topics Research

The establishment of these sites will allow for access to experimental treatments for people living with ALS in the state of Minnesota and surrounding areas, as well as the collection of safety and biomarker data.



<complex-block>

Healey PT Companion EA Sites

ALS Expanded Access Progress

- Act for ALS was signed into law in dec. 2021 providing substantial funding for EAPs
- As of May 2024, over 400 participants have enrolled in EAPs across 21 investigational therapies [2x increase vs 2022]
- 45 sites are planned across the U.S. for the Pridopidine EAP and 10 are planned for RAPA-501 EAP [7x increase vs 2022]
- Even with this great progress, less than 10% of eligible ALS patients will have access to expanded access => more work to do!





4 Active Clinical Sites



21 Investigational Products

What's Next?

- Now widening scope of TechVsALS fundraising to support an innovative new Healey Platform Trial accelerator program
- Provide multi-year funding to augment staffing and infrastructure at leading sites
- Our goal: greatly <u>accelerate trial enrollment</u> and <u>increase EAP</u> access for all ALS patients



<u>www.techvsals.org</u> shawn@techvsals.org

Here's how you can help!

- Help us connect to companies, foundations
- Join our team awareness, outreach, grassroots fundraising
- Donate today! Every dollar counts and goes directly to the Healey Center <u>www.techvsals.org</u>



<u>www.techvsals.org</u> shawn@techvsals.org

Thank you!

For more info, please contact Shawn Sarbacker, <u>shawn@techvsals.org</u> Alexandra Van Strein, <u>avanstrein@mgh.harvard.edu</u> www.techvsals.org